Expert Review of Cardiovascular Therapy最新文献_第10页

Contemporary outcomes of long-term anticoagulation in COVID-19 patients: a regression matched sensitivity analysis of the national inpatient sample. 新冠肺炎患者长期抗凝治疗的当代结果：全国住院患者样本的回归匹配敏感性分析。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-07-10 DOI: 10.1080/14779072.2023.2234282

Amro Taha, Irisha Badu, Harigopal Sandhyavenu, Varun Victor, Sanchit Duhan, Lalitsiri Atti, Hasham Masood Qureshi, Thatiana Schulze Goni, Bijeta Keisham, Vasantha Sandhya Venu, Harshith Thyagaturu, Karthik Gonuguntla, Waqas Ullah, Himanshu Deshwal, Sudarshan Balla

{"title":"Contemporary outcomes of long-term anticoagulation in COVID-19 patients: a regression matched sensitivity analysis of the national inpatient sample.","authors":"Amro Taha, Irisha Badu, Harigopal Sandhyavenu, Varun Victor, Sanchit Duhan, Lalitsiri Atti, Hasham Masood Qureshi, Thatiana Schulze Goni, Bijeta Keisham, Vasantha Sandhya Venu, Harshith Thyagaturu, Karthik Gonuguntla, Waqas Ullah, Himanshu Deshwal, Sudarshan Balla","doi":"10.1080/14779072.2023.2234282","DOIUrl":"10.1080/14779072.2023.2234282","url":null,"abstract":"Background: The role of oral anticoagulation during the COVID-19 pandemic has been debated widely. We studied the clinical outcomes of COVID-19 hospitalizations in patients who were on long-term anticoagulation.Research design and methods: The Nationwide Inpatient Sample (NIS) database from 2020 was queried to identify COVID-19 patients with and without long-term anticoagulation. Multivariate regression analysis was used to calculate the adjusted odds ratio (aOR) of in-hospital outcomes.Results: Of 1,060,925 primary COVID-19 hospitalizations, 102,560 (9.6%) were on long-term anticoagulation. On adjusted analysis, COVID-19 patients on anticoagulation had significantly lower odds of in-hospital mortality (aOR 0.61, 95% CI 0.58-0.64, P < 0.001), acute myocardial infarction (aOR 0.72, 95% CI 0.63-0.83, P < 0.001), stroke (aOR 0.79, 95% CI 0.66-0.95, P < 0.013), ICU admissions, (aOR 0.53, 95% CI 0.49-0.57, P < 0.001) and higher odds of acute pulmonary embolism (aOR 1.47, 95% CI 1.34-1.61, P < 0.001), acute deep vein thrombosis (aOR 1.17, 95% CI 1.05-1.31, P = 0.005) compared to COVID-19 patients who were not on anticoagulation.Conclusions: Compared to COVID-19 patients not on long-term anticoagulation, we observed lower in-hospital mortality, stroke and acute myocardial infarction in COVID-19 patients on long-term anticoagulation. Prospective studies are needed for optimal anticoagulation strategies in hospitalized patients.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9922322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What's the optimal duration of anticoagulation in patients with left ventricular thrombus? 左心室血栓患者的最佳抗凝时间是多少？

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-12-13 DOI: 10.1080/14779072.2023.2270906

Fang Qin Goh, Ching-Hui Sia, Mark Y Chan, Leonard Ll Yeo, Benjamin Yq Tan

{"title":"What's the optimal duration of anticoagulation in patients with left ventricular thrombus?","authors":"Fang Qin Goh, Ching-Hui Sia, Mark Y Chan, Leonard Ll Yeo, Benjamin Yq Tan","doi":"10.1080/14779072.2023.2270906","DOIUrl":"10.1080/14779072.2023.2270906","url":null,"abstract":"Introduction: Left ventricular thrombus (LVT) occurs in acute myocardial infarction and in ischemic and non-ischemic cardiomyopathies. LVT may result in embolic stroke. Currently, the duration of anticoagulation for LVT is unclear. This is an important clinical question as prolonged anticoagulation is associated with increased bleeding risks, while premature discontinuation may result in embolic complications.Areas covered: There are no randomized trial data regarding anticoagulation duration for LVT. Guidelines and expert consensus recommend anticoagulation for 3-6 months with cessation of anticoagulation if interval imaging demonstrates thrombus resolution. Cardiac magnetic resonance imaging (CMR) is more sensitive and specific compared to echocardiography for LVT detection, and may be appropriate for high-risk patients. Prolonged anticoagulation may be considered in unresolved protuberant or mobile LVT, and in patients with resolved LVT but persistent depressed left ventricular ejection fraction and/or myocardial akinesia or dyskinesia.Expert opinion: CMR will likely be increasingly used for LVT surveillance to guide anticoagulation duration. Further research is needed to determine which patients with persistent LVT on CMR benefit from prolonged anticoagulation.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41195888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidence of muscle symptoms in placebo arm among statin-intolerant patients: a systematic review with meta-analysis. 他汀类药物不耐受患者中安慰剂组肌肉症状的发生率：一项荟萃分析系统综述。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-12-10 DOI: 10.1080/14779072.2023.2274502

Rita Louro, Ryan Gouveia E Melo, Jorge Ruivo, Ana G Almeida, Fausto J Pinto, Daniel Caldeira

{"title":"Incidence of muscle symptoms in placebo arm among statin-intolerant patients: a systematic review with meta-analysis.","authors":"Rita Louro, Ryan Gouveia E Melo, Jorge Ruivo, Ana G Almeida, Fausto J Pinto, Daniel Caldeira","doi":"10.1080/14779072.2023.2274502","DOIUrl":"10.1080/14779072.2023.2274502","url":null,"abstract":"Introduction: Statins are highly used in cardiovascular prevention. Statin intolerance is the most significant cause of decreased adherence, translating into a higher cardiovascular risk. This systematic review aims to estimate the incidence of muscle adverse events in patients with a history of statin intolerance receiving placebo.Methods: Database search was performed in CENTRAL, MEDLINE, and EMBASE until March 2023. This systematic review included blinded randomized control trials enrolling patients with a history of statin intolerance who received a placebo. A random-effects meta-analysis was performed. Results were presented in percentages, with 95% confidence intervals (95% CI).Results: Overall, eight studies with 8095 patients with a history of statin intolerance receiving placebo were included. The muscle adverse events incidence rate was 21.34% (95% CI 13.26-30.63%, 8 studies), and discontinuation due to adverse muscle events was 6.12% (95% CI 1.22-13.70%, 3 studies). The incidence was higher in subcutaneous placebo/sham (41.67%, 1 study) compared to oral placebo studies (22.95%, 6 studies).Conclusion: In patients previously labeled as statin-intolerant, about a fifth of the patients exhibited muscle symptoms when receiving a placebo. This highlights the importance of ruling out non-statin-related symptoms to further optimize statin therapy for cardiovascular risk improvement.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71422003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vascular protection with rivaroxaban in the comprehensive management of atrial fibrillation. 利伐沙班在心房颤动综合治疗中的血管保护作用。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-12-10 DOI: 10.1080/14779072.2023.2276893

Carlos Escobar-Cervantes, Pablo Díez-Villanueva, Clara Bonanad Lozano, Antonio Pose Reino, Manuel Almendro-Delia, Lorenzo Facila, Alfonso Valle, Carmen Suárez

{"title":"Vascular protection with rivaroxaban in the comprehensive management of atrial fibrillation.","authors":"Carlos Escobar-Cervantes, Pablo Díez-Villanueva, Clara Bonanad Lozano, Antonio Pose Reino, Manuel Almendro-Delia, Lorenzo Facila, Alfonso Valle, Carmen Suárez","doi":"10.1080/14779072.2023.2276893","DOIUrl":"10.1080/14779072.2023.2276893","url":null,"abstract":"Introduction: In addition to an increased risk of thromboembolic complications, patients with atrial fibrillation (AF) are at risk for vascular events. Consequently, complete vascular protection is warranted in these patients.Areas covered: A narrative search was conducted on PubMed (MEDLINE), using the MeSH terms [Rivaroxaban] + [Atrial fibrillation] + [Cardiovascular] + [Vascular] + [Treatment]. Original data from clinical trials, prospective and retrospective studies, useful reviews and experimental studies, were selected.Expert opinion: The ROCKET-AF trial showed that rivaroxaban is effective in reducing the risk of stroke, with a lower risk of fatal and intracranial bleeding compared to warfarin. Remarkably, experimental data have provided a number of pathogenic mechanisms through which rivaroxaban could provide beneficial vascular properties beyond its antithrombotic activity. Moreover, in the AF population, additional to its ability to reduce the risk of thromboembolic complications, rivaroxaban is associated with a lower risk of myocardial infarction, major adverse cardiac and limb events, and vascular mortality in patients with diabetes, also attenuating renal impairment during follow-up. These findings suggest that rivaroxaban may provide a comprehensive vascular protection in patients with AF.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71479812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sex differences in permanent pacemaker implantation after transcatheter aortic valve replacement: a systematic review and meta-analysis. 经导管主动脉瓣置换术后植入永久性起搏器的性别差异：一项系统综述和荟萃分析。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-08-30 DOI: 10.1080/14779072.2023.2250719

Frederick Berro Rivera, Sung Whoy Cha, John Paul Aparece, Jacques Simon T Gonzales, Wailea Faye C Salva, Nathan Ross B Bantayan, Genquen Phillip Carado, Vikram Sharma, Abdullah Al-Abcha, Michael Lawrenz Co, Fareed Moses S Collado, Annabelle Santos Volgman

{"title":"Sex differences in permanent pacemaker implantation after transcatheter aortic valve replacement: a systematic review and meta-analysis.","authors":"Frederick Berro Rivera, Sung Whoy Cha, John Paul Aparece, Jacques Simon T Gonzales, Wailea Faye C Salva, Nathan Ross B Bantayan, Genquen Phillip Carado, Vikram Sharma, Abdullah Al-Abcha, Michael Lawrenz Co, Fareed Moses S Collado, Annabelle Santos Volgman","doi":"10.1080/14779072.2023.2250719","DOIUrl":"10.1080/14779072.2023.2250719","url":null,"abstract":"Background: There is limited evidence on the effect of sex on permanent pacemaker implantation (PPMI) after transcatheter aortic valve replacement (TAVR). The primary objective of this meta-analysis was to determine the role of sex among patients requiring PPMI post-TAVR.Methods: A literature search was conducted using the SCOPUS, MEDLINE, and CINAHL databases for studies published until October 2022. Eligible studies included published randomized controlled trials (RCTs) and Observational Cohort Studies (OCS) articles that reported PPMI as an outcome of pacemaker status following TAVR. This study was performed per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Guidelines. Publication bias was estimated using a Funnel plot and Egger's test. Data were pooled using a random-effects model. The primary endpoint was the sex difference in PPMI after TAVR, with odds ratios and 95% confidence intervals (CIs) extracted.Results: Data was obtained from 63 studies, and a total of 79,655 patients were included. The cumulative PPMI rate was 15.5% (95% CI, 13.6%-17.7%). The pooled analysis revealed that while there were more females than males undergoing TAVR (51.6%, 95% CI 50.4%-52.8%), males have a 14.5% higher risk for post-TAVR PPMI than females (OR 1.145, 95% CI 1.047-1.253, P < 0.01).Conclusions: Males are more likely to experience PPMI after TAVR than females. Further research needs to be done to better explain these observed differences in outcomes.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10217049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The cardiovascular consequences of electronic cigarette smoking: a narrative review. 电子烟对心血管的影响：叙述性综述。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-10-26 DOI: 10.1080/14779072.2023.2264179

Petros Fountoulakis, Panagiotis Theofilis, Sotiris Tsalamandris, Alexios S Antonopoulos, Panagiotis Tsioufis, Konstantinos Toutouzas, Evangelos Oikonomou, Konstantinos Tsioufis, Dimitris Tousoulis

{"title":"The cardiovascular consequences of electronic cigarette smoking: a narrative review.","authors":"Petros Fountoulakis, Panagiotis Theofilis, Sotiris Tsalamandris, Alexios S Antonopoulos, Panagiotis Tsioufis, Konstantinos Toutouzas, Evangelos Oikonomou, Konstantinos Tsioufis, Dimitris Tousoulis","doi":"10.1080/14779072.2023.2264179","DOIUrl":"10.1080/14779072.2023.2264179","url":null,"abstract":"Introduction: E-cigarettes have emerged as a popular alternative to traditional tobacco smoking in recent years. Despite their growing popularity, concerns have arisen regarding the cardiovascular implications of e-cigarette use.Areas covered: This narrative review aims to highlight the latest evidence on the impact of e-cigarettes on cardiovascular health.Expert opinion: Numerous studies have demonstrated that e-cigarette use can lead to acute adverse cardiovascular effects. Inhalation of e-cigarette aerosols exposes users to a wide range of potentially harmful substances that have been implicated in critical pathophysiologic pathways of cardiovascular disease, namely endothelial dysfunction, oxidative stress, inflammation, sympathetic overdrive, and arterial stiffness. While long-term epidemiological studies specifically focusing on the cardiovascular effects of e-cigarettes are still relatively scarce, early evidence suggests a potential association between e-cigarette use and an increased risk of adverse cardiovascular events. However, it is essential to recognize that e-cigarettes are relatively new products, and the full extent of their long-term cardiovascular impact has not been fully elucidated. In the meantime, promoting tobacco cessation strategies that are evidence-based and regulated, along with rigorous monitoring of e-cigarette use patterns and associated health outcomes, are essential steps in safeguarding cardiovascular health in the face of this emerging public health challenge.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41108978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In response to: preventing atrial fibrillation in COVID-19: exploring the role of interleukin-6 receptor antagonists. 针对：预防新冠肺炎心房颤动：探索白细胞介素-6受体拮抗剂的作用。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-10-26 DOI: 10.1080/14779072.2023.2264761

Praveen Gupta, Anunay Gupta, Sandeep Bansal, Sumita Saluja, Kapil Gupta

引用次数: 0

Redo transcatheter aortic valve replacement in degenerated transcatheter bioprosthesis (TAV-in-TAV). 在退化的经导管生物瓣膜（TAV中的TAV）中恢复经导管主动脉瓣置换术。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-10-26 DOI: 10.1080/14779072.2023.2266368

Juan Sánchez-Ceña, Lluis Asmarats, Chi Hion Pedro Li, Xavier Millán, Estefanía Fernández-Peregrina, Irene Menduiña, Albert Massó van Roessel, Dabit Arzamendi

{"title":"Redo transcatheter aortic valve replacement in degenerated transcatheter bioprosthesis (TAV-in-TAV).","authors":"Juan Sánchez-Ceña, Lluis Asmarats, Chi Hion Pedro Li, Xavier Millán, Estefanía Fernández-Peregrina, Irene Menduiña, Albert Massó van Roessel, Dabit Arzamendi","doi":"10.1080/14779072.2023.2266368","DOIUrl":"10.1080/14779072.2023.2266368","url":null,"abstract":"Introduction: With the expanding indications of transcatheter aortic valve replacement (TAVR) to younger and low-risk patients, the life expectancy of patients currently undergoing TAVR will likely outlive the durability of transcatheter bioprosthesis. Consequently, the number of failed transcatheter bioprosthesis requiring surgical valve explant or redo TAVR is expected to increase.Areas covered: The aim of this review is to provide an updated overview of redo TAVR for treating degenerated transcatheter bioprosthesis, focusing on pre-procedural planning, potential challenges of coronary reaccess during TAVR-in-TAVR and main outcomes of TAVR explant and redo TAVR.Expert opinion: Patient-tailored device selection and individualized implantation height should be carefully assessed during the index TAVR procedure (weighting between pacemaker avoidance and the potential risk of coronary occlusion in future TAVR-in-TAVR). Future prospective studies comparing safety and clinical outcomes between redo TAVR vs TAVR explant are eagerly awaited.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41182317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assisted reproductive technology: what are the cardiovascular risks for women? 辅助生殖技术：女性的心血管风险是什么？

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-10-26 DOI: 10.1080/14779072.2023.2266355

Carolyn Guan, Carla Rodriguez, Petal Elder-Odame, Anum S Minhas, Salman Zahid, Valerie L Baker, Chrisandra L Shufelt, Erin D Michos

{"title":"Assisted reproductive technology: what are the cardiovascular risks for women?","authors":"Carolyn Guan, Carla Rodriguez, Petal Elder-Odame, Anum S Minhas, Salman Zahid, Valerie L Baker, Chrisandra L Shufelt, Erin D Michos","doi":"10.1080/14779072.2023.2266355","DOIUrl":"10.1080/14779072.2023.2266355","url":null,"abstract":"Introduction: Infertility affects 15% of women of reproductive age in the United States. The use of assisted reproductive technology (ART) has been rising globally, as well as a growing recognition of reproductive factors that increase risk for cardiovascular disease (CVD).Areas covered: Women with infertility who use ART are more likely to have established CVD risk factors, such as obesity, dyslipidemia, hypertension, and diabetes. They are also more likely to experience adverse pregnancy outcomes, which are associated with both peripartum and long-term cardiovascular complications. ART may lead to increased cardiometabolic demands due to ovarian stimulation, pregnancy itself, and higher rates of multifetal gestation. Preeclampsia risk appears greater with frozen rather than fresh embryo transfers.Expert opinion: The use of ART and its association with long term CVD has not been well-studied. Future prospective and mechanistic studies investigating the association of ART and CVD risk may help determine causality. Nevertheless, CVD risk screening is critical pre-pregnancy and during pregnancy to reduce pregnancy complications that elevate future CVD risk. This also offers a window of opportunity to connect patients to longitudinal care for early management of cardiometabolic risk profile and initiation of preventive lifestyle and pharmacotherapy interventions tailored toward patient-specific risk factors.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615881/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41107616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The current and future status of inotropes in heart failure management. inotropes在心力衰竭管理中的现状和未来。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-07-23 DOI: 10.1080/14779072.2023.2237869

Angelos Arfaras-Melainis, Ioannis Ventoulis, Effie Polyzogopoulou, Antonios Boultadakis, John Parissis

{"title":"The current and future status of inotropes in heart failure management.","authors":"Angelos Arfaras-Melainis, Ioannis Ventoulis, Effie Polyzogopoulou, Antonios Boultadakis, John Parissis","doi":"10.1080/14779072.2023.2237869","DOIUrl":"10.1080/14779072.2023.2237869","url":null,"abstract":"Introduction: Heart failure (HF) is a complex syndrome with a wide range of presentations and acuity, ranging from outpatient care to inpatient management due to acute decompensated HF, cardiogenic shock or advanced HF. Frequently, the etiology of a patient's decompensation is diminished cardiac output and peripheral hypoperfusion. Consequently, there is a need for use of inotropes, agents that increase cardiac contractility, optimize hemodynamics and ensure adequate perfusion.Areas covered: Inotropes are divided into 3 major classes: beta agonists, phosphodiesterase III inhibitors and calcium sensitizers. Additionally, as data from prospective studies accumulates, novel agents are emerging, including omecamtiv mecarbil and istaroxime. The aim of this review is to summarize current data on the optimal use of inotropes and to provide an expert opinion regarding their current and future use in the management of HF.Expert opinion: The use of inotropes has long been linked to worsening mortality, tachyarrhythmias, increased myocardial oxygen consumption and ischemia. Therefore, individualized and evidence-based treatment plans for patients who require inotropic support are necessary. Also, better quality data on the use of existing inotropes is imperative, while the development of newer and safer agents will lead to more effective management of patients with HF in the future.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9934258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1